Biopetrolia
  • Home
  • About Us
    • Who We Are
    • Our Technology
  • Products
  • Partners
    • Services
    • Collaborations
  • News
  • Contact
June 2, 2017

Production of the antiviral drug Docosanol through yeast fermentation

Production of the antiviral drug Docosanol through yeast fermentation
June 2, 2017

Chalmers and Biopetrolia researchers successfully engineered yeast cells for production of Docosanol with increased efficiency and selectivity, as reported by the paper in Nature Communications. Docosanol is a very long chain fatty alcohol mostly used as an emollient, emulsifier, and thickener in cosmetics. It is also commercialized as an FDA-approved antiviral agent for treatment of herpes simplex virus symptoms.

For producing docosanol, yeast cells were first engineered to produce very long chain fatty acids, which are present in only very low levels in the native cells. Subsequent engineering led to the conversion of said fatty acids into their fatty alcohol form in a very specific way free of contaminants from similar molecules.

Read the original article from Nature Communications

Previous articleBiopetrolia CEO featured as one of Top Young Researchers Making Names for Themselves in IndustryNext article Major investment in research to make Sweden a leader in biologics

Recent News

We’re hiring again!December 22, 2020
Jens Nielsen to receive award for metabolic engineeringOctober 16, 2020
We’re hiring!September 1, 2020
Biopetrolia

Connect

Contact

Biopetrolia AB
Kemivägen 10
412 58 Göteborg
Sweden
info@biopetrolia.com